ORGANON TICE BCG VACCINE RECOMMENDED FOR RECURRENT PAPILLARY BLADDER CARCINOMA BASED ON ONE TRIAL; INFECTIOUS DISEASE CONTACTS TO BE LISTED IN LABELING
A single pivotal trial of Organon's Tice Bacillus-Calmette Guerin vaccine for intravesical installation against recurrent papillary carcinoma of the bladder is sufficient to support approval, FDA's Oncologic Drugs Advisory Committee agreed Dec. 16.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth